Evidence map›Paper›PMID 35831825›Full record

ArticleBMC medical genomics2022

Identifying the role of transient receptor potential channels (TRPs) in kidney renal clear cell carcinoma and their potential therapeutic significances using genomic and transcriptome analyses.

Jie Ren, Qihang Yuan, Jifeng Liu, Lei Zhong, Hanshuo Li, Guangzhen Wu, Feng Chen, Qizhen Tang

Open access · goldAbstract read
In one paragraph

Article in BMC medical genomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jie Ren *Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Qihang Yuan *Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Jifeng Liu *Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Lei ZhongDepartment of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Hanshuo LiDepartment of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Guangzhen WuDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. wuguang0613@hotmail.com.
Feng ChenDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. dmuchenfeng@163.com.
Qizhen TangDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. lnfstqz@163.com.
Dalian Medical University · CNFirst Affiliated Hospital of Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney renal clear cell carcinoma (KIRC) is among the major causes of cancer-caused mortality around the world. Transient receptor potential channels (TRPs), due to their role in various human diseases, might become potential drug targets in cancer. The mRNA expression, copy number variation, single-nucleotide variation, prognostic values, drug sensitivity, and pathway regulation of TRPs were studied across cancer types. The ArrayExpress and The Cancer Genome Atlas (TCGA) databases were used to retrieve KIRC samples. Simultaneously, training, internal, and external cohorts were grouped. In KIRC, a prognostic signature with superior survival prediction in contrast with other well-established signatures was created after a stepwise screening of optimized genes linked to TRPs using univariate Cox, weighted gene co-expression network analysis, multivariate Cox, and least absolute shrinkage and selection operator regression analyses. Subsequent to the determination of risk levels, the variations in the expression of immune checkpoint genes, tumor mutation burden, and immune subtypes and response between low-risk and high-risk subgroups were studied using a variety of bioinformatics algorithms, including ESTIMATE, XCELL, EPIC, CIBERSORT-ABS, CIBERSORT, MCPCOUNTER, TIMER, and QUANTISEQ. Gene set enrichment analysis helped in the identification of abnormal pathways across the low- and high-risk subgroups. Besides, high-risk KIRC patients might benefit from ABT888, AZD6244, AZD7762, Bosutinib, Camptothecin, CI1040, JNK inhibitor VIII, KU55933, Lenalidomide, Nilotinib, PLX4720, RO3306, Vinblastine, and ZM.447439; however, low-risk populations might benefit from Bicalutamide, FH535, and OSI906. Finally, calibration curves were used to validate the nomogram with a satisfactory predictive survival probability. In conclusion, this research provides useful insight that can aid and guide clinical practice and scientific research.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsTransient Receptor Potential ChannelsDNA Copy Number VariationsGene Expression ProfilingGene Expression Regulation, NeoplasticGenomicsHumansKidneyPrognosisTranscriptomeTransient Receptor Potential ChannelsBioinformaticsKidney renal clear cell carcinomaPrognisisTransient receptor potential channels

Identifiers

PMID35831825
PMCPMC9277847
OpenAlexW4285087842

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.